Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 202

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

Open access
Rejeski, Kai, Perez, Ariel, Iacoboni, Gloria, Penack, Olaf, Bücklein, Veit, Jentzsch, Liv, Mougiakakos, Dimitrios, Johnson, Grace, Arciola, Brian, Carpio, Cecilia, Blumenberg, Viktoria, Hoster, Eva, Bullinger, Lars, Locke, Frederick L, von Bergwelt-Baildon, Michael, Mackensen, Andreas, Bethge, Wolfgang, Barba, Pere, Jain, Michael D, Subklewe, Marion · 2022 · Journal for ImmunoTherapy of Cancer

Abstract

Background: CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) represents a promising treatment modality for an increasing number of B-cell malignancies. However, prolonged cytopenias and infections substantially contribute to the toxicity burden of CAR-T. The recently developed CAR-HEMATOTOX (HT) score—composed of five pre-lymphodepletion variables (eg, absolute neutrophil count, platelet count, hemoglobin, C-reactive protein, ferritin)—enables risk stratification of hematological toxicity. Methods: In this multicenter retrospective analysis, we characterized early infection events (days 0–90) and clinical outcomes in 248 patients receiving standard-of-care CD19 CAR-T for relapsed/refractory large B-cell lymphoma. This included a derivation cohort (cohort A, 179 patients) and a second independent validation cohort (cohort B, 69 patients). Cumulative incidence curves were calculated for all-grade, grade ≥3, and specific infection subtypes. Clinical outcomes were studied via Kaplan-Meier estimates. Results: In a multivariate analysis adjusted for other baseline features, the HT score identified patients at high risk for severe infections (adjusted HR 6.4, 95% CI 3.1 to 13.1). HT high patients more frequently developed severe infections (40% vs 8%, p<0.0001)—particularly severe bacterial infections (27% vs 0.9%, p<0.0001). Additionally, multivariate analysis of post-CAR-T factors revealed that infection risk was increased by prolonged neutropenia (≥14 days) and corticosteroid use (≥9 days), and decreased with fluoroquinolone prophylaxis. Antibacterial prophylaxis significantly reduced the likelihood of severe bacterial infections in HT high (16% vs 46%, p<0.001), but not HT low patients (0% vs 2%, p=n.s.). Collectively, HT high patients experienced worse median progression-free (3.4 vs 12.6 months) and overall survival (9.1 months vs not-reached), and were hospitalized longer (median 20 vs 16 days). Severe infections represented the most common cause of non-relapse mortality after CAR-T and were associated with poor survival outcomes. A trend toward increased non-relapse mortality in HT high patients was observed (8.0% vs 3.7%, p=0.09). Conclusions: These data demonstrate the utility of the HT score to risk-stratify patients for infectious complications and poor survival outcomes prior to CD19 CAR-T. High-risk patients likely benefit from anti-infective prophylaxis and should be closely monitored for potential infections and relapse.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2021-004475

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 202

Metadata

Authors
Rejeski, K., Perez, A., Iacoboni, G., Penack, O., Bücklein, V., Jentzsch, L., Mougiakakos, D., Johnson, G., Arciola, B., Carpio, C., Blumenberg, V., Hoster, E., Bullinger, L., Locke, F. L., von Bergwelt-Baildon, M., Mackensen, A., Bethge, W., Barba, P., Jain, M. D., & Subklewe, M.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2022-05
Volume
10
Issue
5
Pages
e004475
ISSN
2051-1426 (ISSN-L)
OpenAlex
W4280565316
Cited by
202
References
6
FWCI
14.50
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. https://app.cochat.ai/papers/10.1136/jitc-2021-004475
The paper
Rejeski, K., Perez, A., Iacoboni, G., Penack, O., Bücklein, V., Jentzsch, L., Mougiakakos, D., Johnson, G., Arciola, B., Carpio, C., Blumenberg, V., Hoster, E., Bullinger, L., Locke, F. L., von Bergwelt-Baildon, M., Mackensen, A., Bethge, W., Barba, P., Jain, M. D., & Subklewe, M. (2022). The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2021-004475

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.